Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FHCC9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,591
Award facts
- Contract value 100% obligated
- $11,591.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded a delivery order valued at $11,591.04 by the Defense Logistics Agency on January 26, 2026, for NUCALA 100 mg/mL auto-injectors. The contract utilizes firm fixed-price pricing with no set-aside designation, indicating the company competed in unrestricted federal procurement. The delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide pharmaceutical and medical supply support to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group holds a single-award IDC under the PPV-G GEN V program with a ceiling value of $499,999,999 and completion date of December 31, 2036, featuring a 30-month base period and three 30-month option periods. The company's established capability in supplying specialized pharmaceutical products—including immunosuppressants, biologics, oncology treatments, and emergency medications—to military healthcare operations demonstrates its role as a critical supplier within the federal pharmaceutical supply chain. This delivery order for NUCALA, an immunosuppressant biologic agent, represents routine fulfillment under the broader contract vehicle supporting the Department of Defense's medical supply requirements.
Quick answers
Who was awarded contract SPE2DR26FHCC9?
SPE2DR26FHCC9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 26, 2026.
How much is contract SPE2DR26FHCC9 worth?
The government has obligated $11,591 on SPE2DR26FHCC9.
Is contract SPE2DR26FHCC9 an order under another contract?
Yes. SPE2DR26FHCC9 is a delivery order under SPE2DR25D9205, an indefinite delivery contract.
Was contract SPE2DR26FHCC9 competed?
The extent of competition for SPE2DR26FHCC9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award